EXAS - Exact Sciences Corp.
IEX Last Trade
61.71
-0.550 -0.891%
Share volume: 2,201,046
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$62.26
-0.55
-0.88%
Fundamental analysis
8%
Profitability
0%
Dept financing
35%
Liquidity
38%
Performance
1%
Performance
5 Days
3.33%
1 Month
32.44%
3 Months
36.33%
6 Months
9.55%
1 Year
-25.51%
2 Year
73.38%
Key data
Stock price
$61.71
DAY RANGE
N/A - N/A
52 WEEK RANGE
$40.62 - $85.15
52 WEEK CHANGE
-$0.28
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: Kevin Conroy
Region: US
Website: https://www.exactsciences.com/
Employees: 5,120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.exactsciences.com/
Employees: 5,120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
Recent news